Superworth

Arrowhead Pharmaceuticals profit margin ARWR

Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.

Net margin, 12 months
−47.8%
Operating margin, 12 months
−33.8%
Net margin on a year earlier
−21.9 pts
Peer median
15.0%

Over the twelve months to Jun 30, 2026, Arrowhead Pharmaceuticals kept −47.8% of its revenue as net profit, with an operating margin of −33.8%.

The median for 10 large drugmakers of a similar size is 15.0%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−0.2%11.9%
FY2024n/an/a
FY2023−85.3%−85.2%
FY2022−72.4%−73.4%
FY2021n/an/a
FY2020−96.1%n/a
FY201940.3%36.3%
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q3 FY26−47.8%−21.9 pts−33.8%
Q2 FY26−48.4%−22.0 pts−35.7%
Q1 FY2618.5%n/a27.6%
Q4 FY25−0.2%n/a11.9%
Q3 FY25−25.9%n/a−18.8%
Q2 FY25−26.4%n/a−21.7%
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23−85.3%−12.9 pts−85.2%

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

CompanyProfit margin
ARWRArrowhead Pharmaceuticals−47.8%
TGTXTG Therapeutics55.2%
PTGXProtagonist Therapeutics29.4%
ALKSAlkermes plc.4.0%
CORTCorcept Therapeutics6.6%
AMRXAmneal Pharmaceuticals5.0%
BMRNBiomarin Pharmaceutical2.1%
LGNDLigand Pharmaceuticals67.9%
KNSAKiniksa Pharmaceuticals International9.6%
JAZZJazz Pharmaceuticals20.4%
INDVIndivior Pharmaceuticals26.7%
Peer median15.0%

Where Arrowhead Pharmaceuticals ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.